Premium
Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
Author(s) -
Elble Rodger J.,
Suchowersky Oksana,
Shaftman Stephanie,
Weiner William J.,
Huang Peng,
Tilley Barbara
Publication year - 2010
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22997
Subject(s) - neuroprotection , parkinson's disease , rating scale , intervention (counseling) , placebo , disease , medicine , degenerative disease , clinical trial , psychology , physical therapy , psychiatry , alternative medicine , pathology , developmental psychology
We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q 10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society